Table 1.
Participant characteristics, by vaccine type and overall (n = 9101).
| Characteristic | ChAdOx1 (n = 5770) |
BNT162b2 (n = 3331) |
Overall (n = 9101) |
|
|---|---|---|---|---|
| Age | Median age, years (IQR) | 63.5 (57.0–68.9) | 65.5 (57.4–71.6) | 64.2 (57.1–69.9) |
| Age range, years | 17.4 89.4 | 16.6 90.5 | 16.6 90.5 | |
| Sex, n (%) | Male | 1671 (29.0) | 956 (28.7) | 2627 (28.9) |
| Female | 4099 (71.0) | 2375 (71.3) | 6474 (71.1) | |
| Ethnicity, n (%) 1 | White | 5565 (96.4) | 3222 (96.7) | 8787 (96.5) |
| South Asian | 119 (2.1) | 60 (1.8) | 179 (2) | |
| Black/African/Caribbean/Black British | 62 (1.1) | 38 (1.1) | 100 (1.1) | |
| Mixed/Multiple/Other | 24 (0.4) | 10 (0.3) | 34 (0.4) | |
| Nation of residence 2 | England | 5177 (89.8) | 2906 (87.3) | 8083 (88.8) |
| Northern Ireland | 39 (0.7) | 78 (2.3) | 117 (1.3) | |
| Scotland | 358 (6.2) | 199 (6.0) | 557 (6.1) | |
| Wales | 194 (3.4) | 147 (4.4) | 341 (3.8) | |
| Body mass index, kg/m2, n (%) 3 | <25 | 2845 (49.3) | 1596 (47.9) | 4441 (48.8) |
| 25–30 | 1881 (32.6) | 1097 (32.9) | 2978 (32.7) | |
| >30 | 1034 (17.9) | 636 (19.1) | 1670 (18.3) | |
| Highest educational level attained, n (%) 4 | Primary/Secondary | 636 (11) | 401 (12) | 1037 (11.4) |
| Higher/Further (A levels) | 857 (14.9) | 441 (13.2) | 1298 (14.3) | |
| College | 2540 (44) | 1500 (45) | 4040 (44.4) | |
| Post-graduate | 1736 (30.1) | 984 (29.5) | 2720 (29.9) | |
| Quantiles of IMD rank, n (%) 5 | Q1 (most deprived) | 1172 (20.3) | 786 (23.6) | 1958 (21.5) |
| Q2 | 1417 (24.6) | 782 (23.5) | 2199 (24.2) | |
| Q3 | 1537 (26.6) | 868 (26.1) | 2405 (26.4) | |
| Q4 (least deprived) | 1639 (28.4) | 893 (26.8) | 2532 (27.8) | |
| Tobacco smoking, n (%) | Non-current/never smoker | 5546 (96.1) | 3194 (95.9) | 8740 (96) |
| Current smoker | 224 (3.9) | 137 (4.1) | 361 (4) | |
| Alcohol consumption/week, units, n (%) | None | 1505 (26.1) | 896 (26.9) | 2401 (26.4) |
| 1–7 | 2018 (35) | 1212 (36.4) | 3230 (35.5) | |
| 8–14 | 1186 (20.6) | 695 (20.9) | 1881 (20.7) | |
| 15–21 | 593 (10.3) | 310 (9.3) | 903 (9.9) | |
| 22–28 | 263 (4.6) | 127 (3.8) | 390 (4.3) | |
| >28 | 205 (3.6) | 91 (2.7) | 296 (3.3) | |
| Self-assessed general health | Excellent | 1183 (20.5) | 654 (19.6) | 1837 (20.2) |
| Very good | 2336 (40.5) | 1315 (39.5) | 3651 (40.1) | |
| Good | 1441 (25.0) | 925 (27.8) | 2366 (26.0) | |
| Fair | 637 (11.0) | 344 (10.3) | 981 (10.8) | |
| Poor | 173 (3.0) | 93 (2.8) | 266 (2.9) | |
| Pre-vaccination anti-spike IgG/A/M serostatus | Negative | 3789 (65.7) | 1770 (53.1) | 5559 (61.1) |
| Positive | 696 (12.1) | 325 (9.8) | 1021 (11.2) | |
| Unknown | 1285 (22.3) | 1236 (37.1) | 2521 (27.7) | |
| Post-vaccination anti-spike IgG/A/M serostatus | Negative | 334 (5.8) | 40 (1.2) | 374 (4.1) |
| Positive | 5436 (94.2) | 3291 (98.8) | 8727 (95.9) | |
| Median inter-dose interval, weeks (IQR) | 11.0 (10.0–11.2) | 10.7 (9.5–11.1) | 11.0 (9.8–11.1) | |
| Median time from date of second vaccine dose to date of sampling, weeks (IQR) | 7.6 (5.7–9.6) | 10.1 (8.3–13.1) | 8.6 (6.4–10.7) | |
Abbreviations: IQR, inter-quartile range; s.d., standard deviation; IMD, index of multiple deprivation; Ig, Immunoglobulin. (1) Ethnicity not reported for n = 1 who received BNT162b2 vaccine. (2) Nation of residence not reported for n = 1 who received BNT162b2 vaccine and n = 2 who received ChAdOx1 vaccine. (3) BMI not reported for n = 10 who received BNT162b2 vaccine and n = 2 who received ChAdOx1 vaccine. (4) Level of education not reported for n = 5 who received BNT162b2 vaccine and n = 1 who received ChAdOx1 vaccine. (5) IMD rank not reported for n = 2 who received BNT162b2 vaccine and n = 5 who received ChAdOx1 vaccine.